This disclosure is directed to N-substituted valiolamine compounds, their use as glycosidase inhibitors, and in methods of treating diseases or conditions in which glycosidase inhibition provides benefit.
本公开涉及N-取代的瓦利奥胺化合物,它们的用途是作为糖苷酶
抑制剂,并用于治疗糖苷酶抑制提供益处的疾病或病况的方法。